Bausch Health (BHC)
(Delayed Data from NYSE)
$7.95 USD
-0.15 (-1.85%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.95 USD
-0.15 (-1.85%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Bausch (BHC) Up 1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $24.05, moving +1.69% from the previous trading session.
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $21.97, marking a -1.08% move from the previous day.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $22.56 in the latest trading session, marking a -0.84% move from the prior day.
Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.
Bausch Health (BHC) Beats Q4 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 17.59% and 0.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $24.74 in the latest trading session, marking a -1.55% move from the prior day.
Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $24.78 in the latest trading session, marking a +1.6% move from the prior day.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $24.39 in the latest trading session, marking a -0.53% move from the prior day.
Bausch Health (BHC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $24.57, marking a +1.78% move from the previous day.
Should Value Investors Pick Bausch Health (BHC) Stock Now?
by Zacks Equity Research
Let's see if Bausch Health Companies Inc. (BHC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Anthem's (ANTM) Q4 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q4 results reflect better revenues and a solid contribution from its Government Business and IngenioRx businesses, partly offset by escalating expenses.
Is a Beat in Store for HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have gained from rising admissions and higher revenues.
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch Health (BHC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $25.06, marking a +0.56% move from the previous day.
Anthem (ANTM) Gears Up for Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results are likely to reflect gains from increased premiums and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.
UnitedHealth (UNH) Q4 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
UnitedHealth's (UNH) Q4 results reflect higher revenues, driven by segmental contributions, partly offset by steep expenses.
Bausch (BHC) Eye Care Business Files for IPO in the US & Canada
by Zacks Equity Research
Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $27.34, moving -1.51% from the previous trading session.
Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $27.79, moving +0.65% from the previous trading session.
Why Is Bausch (BHC) Down 15.6% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.
Bausch Health (BHC) Beats Q3 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 6.54% and -1.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?